anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: group of inventions concerns medicine and can be used in the patient for treatment or prevention of the infection caused by hepatitis type C virus. That is ensured by administration of VX-950 or its pharmaceutically acceptable salt. Each of inventions characterises certain modes of administration of VX-950 to ensure effective treatment of the disease. The declared methods provide maintenance of minimum plasma concentration of VX-950 for 24 hours, decrease of the ALT level, considerable reduction of the RNA plasma level of hepatitis type C virus and enabled steady virus response. ^ EFFECT: preparation of the medicine for treatment or prevention in the patient of the infection caused by hepatitis type C virus. ^ 29 cl, 10 ex, 17 dwg
Sodium oxybate, the sodium salt of GHB, produces dose-dependent central nervous system effects, including hypnotic and positive subjective reinforcing effects. The onset of effect is rapid, enhancing its potential for abuse or misuse.

Drug abuse is the intentional non-therapeutic use of a drug product or substance, even once, for its desirable psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug misuse and abuse may occur with or without progression to addiction. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

The rapid onset of sedation, coupled with the amnestic features of GHB, particularly when combined with alcohol, has proven to be dangerous for the voluntary and involuntary user (e.g., assault victim).

Illicit GHB is abused in social settings primarily by young adults. Some of the doses estimated to be abused are in a similar dosage range to that used for treatment of patients with cataplexy. GHB has some commonalities with ethanol over a limited dose range, and some cross tolerance with ethanol has been reported as well. Cases of severe dependence and craving for GHB have been reported when the drug is taken around the clock. Patterns of abuse indicative of dependence include: 1) the use of increasingly large doses, 2) increased frequency of use, and 3) continued use despite adverse consequences.

Because illicit use and abuse of GHB have been reported, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of GHB (e.g., increase in size or frequency of dosing, drug-seeking behavior, feigned cataplexy). Dispose of Sodium Oxybate Oral Solution according to state and federal regulations. It is safe to dispose of Sodium Oxybate Oral Solution down the sanitary sewer.
The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior therapies, including rituximab.
PURPOSE: A pharmaceutical composition and a food composition containing soluble polysaccharides derived from seaweed fusiforme for preventing and treating obesity are provided to suppress the activity of human pancreatic lipase and weight gain through dietary intake of high fat. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity contains sea weed fusiforme-derived soluble polysaccharides as active ingredients, which are isolated from a sea weed fusiforme extract. The soluble polysaccharides suppress the activity of human pancreatic lipase. The sea weed fusiforme extract is prepared by adding water to sea weed fusiforme and heating at 100-130°C and at pressure of 1-3 atm for 5-60 minutes. A method for preparing the soluble polysaccharides comprises the steps of: filtering the sea weed fusiforme extract to remove insoluble materials; centrifuging the extract at 3000-5000 rpm for 5-15 minutes; adding 2-3 times volume of the alcohol to the supernatant and precipitating; and freeze-drying the precipitate. A food composition for suppressing obesity contains the soluble polysaccharides.
Methods and devices are provided for sensing cardiac events from electrodes located proximate to one or more atrial or ventricular sites, over a period of time that includes a detection period followed by an observation period. One or more processors declare a ventricular arrhythmia episode and a corresponding VT/VF therapy based on the cardiac events during at least the detection period. The processors delay delivery of the VT/VF therapy for a self-termination period within the observation period. The self-termination period represents a time period during which the ventricular arrhythmia episode may self-terminate. The processors analyze a stability characteristic of interest (COI) from the cardiac events sensed over at least a portion the observation period and determine an end point for the self-termination period, within the observation period, based on the stability COI. The VT/VF therapy is delivered when the VT/VF arrhythmia episode continues past the end point.
Participants will be enrolled in a quality assurance program with an online multiple-choice quiz including still-pictures and video sequences of 10 application specific POCUS examinations. Through 15-20 questions, the quiz tests participants (1) knowledge about indications for performing POCUS examinations, (2) applied knowledge of ultrasound equipment, (3) ability to optimize images, (4) ability to recognize and present structures, (5) ability to interpret images, (6) ability to describe and document findings and (7) medical decision-making. Following the quiz, the participants are offered guidance to improve their performance.
A method of producing a rotavirus-like particle (RLP) in a plant is provided. The method comprises expressing within a host or host cell for example a plant, portion of a plant or plant cell one or more nucleic acid comprising one or more regulatory region operatively linked to a first, second and third nucleotide sequence, the regulatory region active in the host or host cell. The first nucleotide sequence encoding a first rotavirus protein, the second nucleotide sequence encoding a second rotavirus protein and the third nucleotide sequence encoding a third rotavirus protein. The first, second and third encode rotavirus protein NSP4 and VP2 or VP6 and VP4 or VP7. The host or host cell is incubated under conditions that permit the expression of the nucleic acids, so that NSP4 and either VP2 of VP6 and VP4 or VP7 are expressed, thereby producing the RLP. Hosts comprising the RLP, compositions comprising the RLP and method for using the composition are also provided.
In this study population, facial paralysis was significantly associated with increased loneliness, decreased social function, decreased comfort with socializing, and worse quality of life scores. Furthermore, prior studies have shown that facial paralysis increases the likelihood of depression as measured on validated psychometric instruments. Currently, treating physicians have several options in addressing the anatomic and physiologic sequela of facial paralysis. However, strategies to address the psychologic and coping ability for patients have not been investigated. To better provide patient-centered care, physicians should consider the psychosocial impact of facial paralysis to identify patients who may benefit from additional support interventions to complement facial reanimation treatment plans.

This is a prospective repeated measures study examining psychosocial status as measured by validated psychometric instruments. The intervention group will participate in mindfulness meditation using a phone application. Assessment of social functioning and quality of life will be conducted using survey instruments.
The Intervention schools: Screened smokers were given Advanced Intervention sessions. After discussion with the State's oral health deputy director and district's programme coordinator, for the purpose of this study, the interval of the Advance Intervention session was decided at 1-month interval.
NK cells and γδT cells are isolated from the patients' PBMCs obtained before standard chemotherapy and then co-cultured ex-vivo. Patients will receive multiple TKC treatments under administration, 3 weeks/cycle. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the investigators. TKC cells are transfused to patients in a dosage escalated manner. Dose escalation starts at 1×10\^8 cells/kg (based on the whole body weight). After the safety assurance of the initial administration, the next course, up to 8 courses, is resumed and the dose maybe increased subsequently at the discretion of the investigators, or reduced for safety reason.
The invention discloses a three-dimensional (3D)-printing-based biocompatible ultrasonic contrast agent. According to the ultrasonic contrast agent, gel serves as a main component to form an outer membrane, and gas is filled in the outer membrane. The invention also discloses a method for preparing the ultrasonic contrast agent. The ultrasonic contrast agent can form a stable microsphere, has the high biocompatibility and a good acoustic response property, is high in drug loading capacity and can serve as an ultrasonic contrast agent, a drug carrier and a preparation. The size of the thin wall of the microsphere is controlled, so that the drug release speed can be controlled. Meanwhile, the invention also provides the method for preparing the ultrasonic contrast agent. The method has the advantages of simplicity, convenience and high production efficiency, the size of the contrast agent can be controlled, and the particle size uniformity of the contrast agent is high.
Confirm the choice of the correct Heparin Sodium Injection vial or cartridge prior to administration of the drug to a patient [see Warnings and Precautions (5.1)]. Heparin Sodium Injection, products must not be confused with "catheter lock flush" products. To lessen this risk for a cartridge, a red cautionary statement has been added to the cartridge and box/bin. Read the cautionary statement and confirm that you have selected the correct medication and strength.

When heparin is added to an infusion solution for continuous intravenous administration, invert the container repeatedly to ensure adequate mixing and prevent pooling of the heparin in the solution.

Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use only if solution is clear and the seal is intact. Do not use if solution is discolored or contains a precipitate. 

Administer Heparin Sodium Injection by intermittent intravenous injection, intravenous infusion, or deep subcutaneous (intrafat, i.e., above the iliac crest or abdominal fat layer) injection. Do not administer Heparin Sodium Injection by intramuscular injection because of the risk of hematoma at the injection site [see Adverse Reactions (6)].
PROBLEM TO BE SOLVED: To obtain the subject antifungal material having antifungal activity against a filamentous fungus such as Trichophyton as a causative of pompholyx by compounding a mortar with a composite polymer emulsion mainly containing an acrylic acid ester copolymer. SOLUTION: This material is obtained by compounding (A) a mortar (preferably, a mixture of a white cement or a Portland cement with quartz sand, iron powder, etc.) with (B) a composite polymer emulsion mainly containing an acrylic acid ester copolymer. Further, the component B is preferably an aqueous solution of an acrylic acid ester copolymer of 25-50% in concentration in terms of a solid component. A mixing ratio of the component B to the component A is preferably 1:1 to 1:6.5. A pompholyx treating device is obtained by forming the antifungal material in such a shape that it can be applied to or be contact with a lesion.
Neoadjuvant therapy for locally advanced colorectal cancer has made great progress in the past 20 years, but there are still limitations such as side effects, organ dysfunction and unsatisfactory control of metastasis. In recent years, with the improvement of surgical techniques and further development of molecular research, how to further improve local control, reduce distant metastasis, and even avoid surgery according to clinical remission to achieve organ preservation, is the current demand and research goal. With the advancement of molecular research, colorectal cancer has different treatment strategies based on microsatellite status. For patients with microsatellite instability locally advanced colorectal cancer, immune checkpoint inhibitor therapy significantly increased the pathologic complete response rate, reduced the incidence of adverse events and improved organ function compared with conventional chemoradiotherapy. For patients with microsatellite stable locally advanced colon cancer, neoadjuvant therapy is still in the exploratory stage. The standard of care is surgery combined with perioperative chemotherapy. For microsatellite stable locally advanced rectal cancer, the complete response rate is improved by enhancing neoadjuvant therapy, which helps to preserve organs. On the other hand, selective radiotherapy preserves organ function and improves quality of life. This article reviews the neoadjuvant treatment strategies for locally advanced colorectal cancer based on organ-sparing strategies.
The present invention relates to an auxiliary medicament for treating tumors, a preparation method thereof and an application thereof. The used raw materials are edible plants of cruciferae and scrophulariaceae, and comprise brassica, india mustard seed, fresh carrot, figwort root and purslane speedwell herb. The raw materials are extracted by water and are extracted and refined by edible alcohol, and thus, a plant extract is prepared. The medicament is emulsified to be processed into soft capsule products. The auxiliary medicament has good effect on preventing and curing various tumors, particularly gastric cancer, lung cancer, liver cancer and leukemia in clinical application, and can compensate for the defects of chemical medicaments at the aspects of cancer prevention and toxicity. The auxiliary medicament has the advantages of high safety, long-term administration, wide resource and low processing cost.
BACKGROUND/AIM: Hair-follicle keratinocytes contain high levels of cysteine, which is derived from methionine, rapidly proliferate, and form the hair shaft. The high proliferation rate of hair-follicle keratinocytes resembles that of aggressive cancer cells. In the present study, we determined the effect of a methionine-deficient diet on hair loss (alopecia) in mice with or without homocysteine supplementation.
MATERIALS AND METHODS: Mice were fed a normal rodent diet (2020X, ENVIGO) (Group 1); a methionine-choline-deficient diet (TD.90262, ENVIGO) (Group 2); a methionine-choline-deficient diet with a 10 mg/kg/day supply of homocysteine administered by intra-peritoneal (i.p.) injection for 2 weeks (Group 3). In Group 2, mice were fed a methionine-choline-deficient diet for an additional 2 weeks but with 10 mg/kg/day of i.p. l-homocysteine and the mice were observed for two additional weeks. Subsequently, the mice were fed a standard diet that included methionine. Hair loss was monitored by photography.
RESULTS: After 14 days, hair loss was observed in Group 2 mice on a methionine-restricted diet but not in Group 3 mice on the methionine-restricted diet which received i.p. homocysteine. In Group 2, at 2 weeks after methionine restriction, hair loss was not rescued by homocysteine supplementation. However, after restoration of methionine in the diet, hair growth resumed. Thus, after 2 weeks of methionine restriction, only methionine restored hair loss, not homocysteine.
CONCLUSION: Hair maintenance requires methionine in the diet. Future experiments will determine the effects of methionine restriction on hair-follicle stem cells.
There is described a formulation comprising a foamable gelling agent (such a s alginate, carageenan or carboxymethylcellulose gels) and a slow-release precipitant therefor. The precipitant is combined with th e gelling agent during foaming and stabilises the foamed form of the gelling agent. Suitable precipitants include calcium salts such as calcium citrate and calcium chloride, or aluminium salts such as aluminium chloride. The increased stability of the foam facilitates sterilisation thereof. Further improvements can be obtained by exposing the cured foam to a precipitant applied externally, optionally washing, and then drying the foam. The foam of the present invention is suitable for medical or veterinary use and can include active ingredients fo r delivery to, for example, a wound site.
Cerebral ischaemia/reperfusion (I/R) injury induces irreversible brain injury and causes functional impairment. Ubiquitination plays a crucial role in protein degradation, but its role in cerebral I/R injury remains unclear. Differentially expressed genes in stroke were identified by analysing the microarray dataset GSE119121. Cerebral I/R was simulated in vitro by treating human microglial HMC3 cells with oxygen-glucose deprivation/reperfusion (OGD/R). Cell viability was tested by Cell Counting Kit 8 (CCK-8) assays, and pyroptosis was examined by flow cytometry. Lactate dehydrogenase (LDH) and inflammatory cytokine secretion were measured by LDH cytotoxicity assays and enzyme-linked immunosorbent assay (ELISA), respectively. The cerebral I/R animal model was established by middle cerebral artery occlusion (MCAO) surgery in rats. Bioinformatic analysis indicated that tripartite motif-containing protein 59 (TRIM59) is downregulated in stroke, which was verified in cerebral I/R models. The upregulation of TRIM59 promoted viability and inhibited pyroptosis in OGD/R-treated microglia and alleviated cerebral I/R injury in vivo. TRIM59 attenuated NOD-like receptor family pyrin domain containing 3 (NLRP3) protein expression through ubiquitination, thus degrading NLRP3 and alleviating OGD/R-induced injury. TRIM59 relieves cerebral I/R injury in vivo and in vivo. Mechanistically, TRIM59 directly interacts with NLRP3 and inhibits NLRP3 through ubiquitination. Targeting the TRIM59/NLRP3 signalling axis may be an effective therapeutic strategy for cerebral I/R.
<P>PROBLEM TO BE SOLVED: To provide a technique for enhancing a foam-forming property at a low temperature and soil-combining performances of foam of a cleansing cosmetic comprising a fatty acid soap as its main cleansing components.  <P>SOLUTION: The cleansing cosmetic comprises 10-30 mass% of a fatty acid soap as a cleansing component, and contains 0.01-5 mass% of a pyroglutamic acid fatty acid polyoxyethylene glyceryl. The fatty acid soap is preferably a mixture of a fatty acid potassium soap and a fatty acid sodium soap. The fatty acid constituting the fatty acid soap preferably comprises isostearic acid and 12-hydroxyfatty acid. The pyroglutamic acid fatty acid polyoxyethylene glyceryl is preferably polyoxyethylene glyceryl pyroglutamate isostearate.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The present invention is based on the discovery that in response different stimuli, dendritic cells initiate various responses by producing different transcription profiles, e.g. IL-2 production by dendritic cells in response to a microbial stimulus. The present invention provides methods of making libraries of gene expression profiles and libraries made thereof corresponding to dendritic cell maturation in response to a microbial stimulation. The present invention provides methods for activating lymphocytes or immune responses and methods for producing II-2 in dendritic cells or preparing dendritic cells for cell-based therapy. The present invention also provides methods and systems for screening agents affecting dendritic cell maturation. In addition, it is the discovery of the present invention that dendritic cells are targets for immunosuppressive virus infections. Accordingly, the present invention provides methods for treating immunosuppressive virus infections or immunosuppression associated with immunosuppressive virus infection. The present invention also provides methods for screening candidate therapeutic agents suitable for treating immunossuppressive virus infection using dendritic cell system.
It is commonly believed that the combination of ADM and psychotherapy is more effective in treating depression than either treatment alone. Data indicate that CT enhances the initial effects of ADM, but little research has been conducted to determine whether prior exposure to CT prevents the onset of new depressive episodes. This study will determine the effectiveness of adding CT to ADM for the treatment of depression.

Participants are randomly assigned to receive either ADM alone or ADM plus CT for up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue cognitive therapy; all recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
The invention provides a health-care wine for warming the stomach. Raw materials of the wine comprise fresh ginger, dried orange peel, clove, brown sugar and fresh wine-making grape. A preparation method comprises the following steps: washing fresh wine-making grape and airing, destemming, and breaking skin to obtain grape pulp; respectively crushing clean fresh ginger, dried orange peel and clove, and fully mixing with grape pulp and brown sugar; adding saccharomycetes and sealingly fermenting in a fermentation tank while controlling fermentation temperature to 25-30 DEG C and fermenting for 10-20 days; after fermentation, squeezing the fermentation product and juicing, filtering a squeezed wine liquid, precipitating, bottling a supernatant and sterilizing. The wine has grape flavor and also has health-care effect on human body due to addition of fresh ginger. If people often drink a proper amount of the wine, human vitality can be enhanced. By adding the above ginger, dried orange peel, clove and brown sugar into the grape wine, the effects of dispelling cold and warming the stomach and invigorating the circulation of blood and the health-care effect of obviously eliminating abdominal distention for people with deficiency-cold in spleen and stomach can be achieved. The wine has efficacy of building human body, has a good taste and pure smell, is suitable for a wide range of people, has rich nutritive value and is a good drink and health-care product.
Compositions and methods for making cDNA from RNA templates, including double-stranded RNA (dsRNA) and single-stranded RNA (ssRNA), are provided. The composition and methods include a recombinant or purified or modified or recombinant RNA dependent RNA polymerases (RdRp's). The RdRp has an amino acid sequence that shares identity to a contiguous segment of the amino acid sequence of one or more Partitiviridae virus RdRps, and includes a reverse transcriptase (RT) domain. Kits including dNTPs for use in generating cDNAs are included. The RdRps can function efficiently at lower temperatures than previously available RT enzymes. Methods of making cDNAs are provided using an RdRp are also provided. RdRps can also be used to identify candidate reverse transcriptase inhibitors.